COMP <GO>
MOLN vs HUMA // GROSS PROFIT MARGIN
Molecular Partners AG (NASDAQ) VS. Humacyte Inc. (NASDAQ) • 15-METRIC TALLY: MOLN 1
— HUMA 1
■ METRIC PARITY
LAST: $3.58 (+1.42%) • MKT CAP: $132.4M
gross-margins
—
LAST: $0.41 (-12.47%) • MKT CAP: $130.5M
gross-margins
-30.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MOLN VS. HUMA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MOLN | HUMA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | -30.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.5 | 51.1 | -9.64 | HUMA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $132.4M | $130.5M | $1.9M | MOLN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MOLN REV | HUMA REV | MOLN GROSS % | HUMA GROSS % | MOLN FCF | HUMA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $2.0M | — | -50.0% | — | -$105.9M |
| FY 2024 | — | $0 | — | — | — | -$99.7M |
| FY 2023 | — | $0 | — | — | — | -$73.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MOLN // BETA —
HUMA // BETA —